Global Stem Cell Therapy Market Size, Share, Opportunities, And Trends By Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), By Application (Musculoskeletal Disorders, Cardiovascular Diseases, Neurological Disorders, Wound Healing, Oncology Disorders, Others), By End-User (Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes And Academic Centers, Others), And By Geography - Forecasts From 2023 To 2028

The stem cell therapy market is anticipated to grow at a steady pace during the forecast period.

The global stem cell therapy market is expanding rapidly as the area of regenerative medicine advances. The use of stem cells to repair or replace damaged cells or tissues in the body is known as stem cell therapy. These adaptable cells can develop into a variety of cell types, providing intriguing therapy possibilities for a variety of illnesses and ailments. The global stem cell therapy market is being pushed by factors such as rising chronic illness incidence, increased awareness of regenerative medicine, and breakthroughs in stem cell research and technology. Furthermore, favorable government laws, increased investment in R&D, and new uses of stem cell treatment all contribute to market growth. With continuing clinical studies and positive treatment outcomes, the global stem cell therapy market is poised for

Growing Aging Population and the Associated Healthcare Burden Enhances the Global Stem Cell Therapy Market Growth.

The global stem cell therapy industry is being driven by a growing aging population and the related healthcare burden. As the world's population ages, so do age-related illnesses and conditions including cardiovascular disease, neurological disease, and orthopaedic problems. By providing regenerative and personalised therapeutic options, stem cell therapy holds considerable potential in treating these age-related health issues. The growing healthcare burden caused by the aging population creates a desire for novel therapeutics that can improve patient outcomes and quality of life. Stem cell treatment provides prospective solutions to these healthcare issues, propelling the global stem cell therapy market forward.

Expansion of Stem Cell-Based Clinical Trials and Research Studies in Global Stem Cell Therapy Market.

The rise of stem cell-based clinical trials and research studies is a major driving force in the worldwide stem cell treatment market. Stem cell research is constantly expanding, and clinical trials are critical in determining the safety and efficacy of stem cell treatments across a wide range of illnesses and disorders. The expanding number of clinical trials and research studies devoted to stem cell treatments indicates the field's increased interest and funding. These trials and research help to enhance scientific understanding, create innovative medicines, and expand therapy options for patients. The increase in stem cell-based clinical trials and research studies propels the global stem cell therapy market forward by clearing the path for novel and evidence-based therapies.

Increasing Investment in Stem Cell Research and Development Boosts the Global Stem Cell Therapy Market Size.

Stem cell research & development spending is growing, which is a major growth element in the worldwide stem cell treatment market. Stem cell research has enormous potential to advance regenerative medicine and revolutionise healthcare. Governments, private investors, and pharmaceutical corporations are increasingly recognising the potential of stem cell treatments and spending heavily on research and development. These investments fund the development of new therapeutic applications, the progress of stem cell production procedures, and the enhancement of treatment protocols. Increasing financial support encourages innovation, accelerates scientific discoveries, and leads to the global stem cell treatment market's growth, eventually helping patients and improving healthcare results.

North America is the Market Leader in the Global Stem Cell Therapy Market.

North America is regarded as the market leader in the global stem cell therapy market. The region is well-known for its excellent healthcare infrastructure, cutting-edge research facilities, and the presence of significant industrial players. Furthermore, North America has favourable regulatory frameworks, payment systems, and a large frequency of chronic illnesses that can be treated with stem cell treatments. The region's emphasis on stem cell research and development, strong investment in regenerative medicine, and successful clinical trials all contribute to the region's leadership in the global stem cell therapy market. Ongoing developments and a favourable market ecology are projected to keep North America at the forefront of the industry.

Collaborations and Partnerships between Industry Players and Research Institutions in the Global Stem Cell Therapy Market.

Collaborations and collaborations between industry participants and research institutes are critical growth drivers in the worldwide stem cell treatment market. Because stem cell research and development are so complicated, they need multidisciplinary expertise, resources, and information exchange. Collaborations between industry participants, such as pharmaceutical corporations, biotechnology businesses, and research institutes, generate synergies and speed the advancement of stem cell treatments. These collaborations allow for the interchange of scientific experience, access to modern technology, and the pooling of resources for clinical trials and the advancement of stem cell research. Collaborations and partnerships generate innovation, improve clinical translation, and fuel the growth of the global stem cell treatment market, eventually helping patients globally by combining industrial knowledge and academic ideas.

Key Developments:

• In May 2023, Pfizer and Thermo Fisher Scientific Inc. announced a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 Latin American, African, Middle Eastern, and Asian countries where advanced genomic testing was previously limited or unavailable. Access to local NGS testing can assist to give quicker analysis of genes related with disease, allowing healthcare practitioners to choose the best medication for that specific patient.
• In February 2023, Globus Medical, a major provider of musculoskeletal solutions, and NUVASIVE, a pioneer in spine technology innovation, announced a formal agreement to merge in an all-stock transaction. The acquisition brings together two well-known musculoskeletal technology firms with a common mission of innovation in the persistent pursuit of unmet clinical requirements to improve patient care.

Company Products:

• TEMCELL® HS Inj.: Mesoblast developed TEMCELL HS Inj. (remestemcel-L), a mesenchymal stem cell treatment. It is licenced to treat paediatric children with acute graft-versus-host disease (aGVHD) who have not responded to steroid therapy. It entails injecting mesenchymal stem cells obtained from healthy adult bone marrow.
• OTEZLA® (apremilast): OTEZLA is an oral medicine produced by Celgene that affects the immune system and has been used in the treatment of some immune-mediated inflammatory illnesses. It is not a stem cell therapy in and of itself.
• MultiStem® Therapy: MultiStem, a patented allogeneic stem cell treatment, is Athersys' flagship product. Adult bone marrow multistem cells have the capacity to stimulate tissue healing and influence the immune system. It is being tested for a number of conditions, including acute respiratory distress syndrome (ARDS), ischemic stroke, and acute myocardial infarction.
• Grafix®: Grafix is a cryopreserved human placental membrane containing a variety of growth factors and cytokines. It is utilized in the treatment of chronic and acute wounds, such as diabetic foot ulcers, as a regenerative therapy.

Segmentation:

• By Type
  • Allogeneic Stem Cell Therapy
  • Autologous Stem Cell Therapy                        
• By Application
  • Musculoskeletal Disorders
  • Cardiovascular Diseases
  • Neurological Disorders
  • Wound Healing
  • Oncology Disorders
  • Others            
• By End-User
  • Hospitals And Clinics
  • Ambulatory Surgical Centers
  • Research Institutes And Academic Centers
  • Others          
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain    
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Taiwan
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Sources

2.3. Research Design

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GLOBAL STEM CELL THERAPY MARKET, BY TYPE

5.1. Introduction

5.2. ALLOGENEIC STEM CELL THERAPY

5.3. AUTOLOGOUS STEM CELL THERAPY                        

6. GLOBAL STEM CELL THERAPY MARKET, BY APPLICATION

6.1. Introduction

6.2. MUSCULOSKELETAL DISORDERS

6.3. CARDIOVASCULAR DISEASES

6.4. NEUROLOGICAL DISORDERS

6.5. WOUND HEALING

6.6. ONCOLOGY DISORDERS

6.7. OTHERS            

7. GLOBAL STEM CELL THERAPY MARKET, BY END-USER

7.1. Introduction

7.2. HOSPITALS AND CLINICS

7.3. AMBULATORY SURGICAL CENTERS

7.4. RESEARCH INSTITUTES AND ACADEMIC CENTERS

7.5. OTHERS          

8. GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Italy

8.4.5. Spain

8.4.6. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia 

8.6.6. Taiwan

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. VERICEL CORPORATION

10.2. OSIRIS THERAPEUTICS, INC. (ACQUIRED BY SMITH & NEPHEW PLC)

10.3. NUVASIVE, INC. (ACQUIRED BY MEDTRONIC PLC)

10.4. MESOBLAST LIMITED

10.5. ATHERSYS, INC.

10.6. CELGENE CORPORATION (ACQUIRED BY BRISTOL MYERS SQUIBB COMPANY)

10.7. JCR PHARMACEUTICALS CO., LTD.

10.8. ANTEROGEN CO., LTD.

10.9. TAKEDA PHARMACEUTICAL COMPANY LIMITED

10.10. ASTELLAS PHARMA INC. 

Vericel Corporation

Osiris Therapeutics, Inc. (Acquired By Smith & Nephew Plc)

Nuvasive, Inc. (Acquired By Medtronic Plc)

Mesoblast Limited

Athersys, Inc.

Celgene Corporation (Acquired By Bristol Myers Squibb Company)

Jcr Pharmaceuticals Co., Ltd.

Anterogen Co., Ltd.

Takeda Pharmaceutical Company Limited

Astellas Pharma Inc.